Desk Score
Maves
Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…
- Semaglutide
- $99/mo (starting dose, first-month rate, compounded)
- Tirzepatide
- Not disclosed
- Coverage
- All 50 states
- Brand-name
- Yes
Weigh Maves against the full ranked field on the best semaglutide providers board, or line it up against its closest alternatives. Or go one-on-one: Maves vs CoreAge Rx.
Desk Score breakdown
Each of the six scored dimensions. See the methodology.
What the Desk likes
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where points come off
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
The Desk's briefing — C+
Best for: Readers who want $99 first-month semaglutide with men's-health and body-optimization framing.
Maves ranks #62 of 498 providers scored — see #1, CoreAge Rx on the board.
Related dispatches
Pricing and verification reflect Maves's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Maves's site. Not medical advice; see our disclosure.